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Supratentorial ependymomas account for a minority of
intracranial ependymomas, which still have uncertain
prognostic markers. Among them, epidermal growth
factor receptor (EGFR) overexpression correlates with a
poor prognosis. In glioblastoma cells, EGFR function
has been reported to be regulated by its migration from
cell membrane infoldings called caveolae and by its colo-
calization with the caveolae-associated protein caveolin-1
(cav-1). Therefore, we decided to investigate cav-1
expression and coexpression with EGFR in a series of
adult intracranial ependymomas. We analyzed 22 adult
supratentorial ependymomas and compared tumor
grades as determined by the WHO classification and
patient survival rates with the expression of EGFR, cav-
1, and p53 and the values of the proliferation marker
Ki-67, all tested by immunohistochemistry; in addition,
we investigated the mutational profile of cav-1. The
results demonstrate that the tumor grade is directly corre-
lated with EGFR, Ki-67, and cav-1 expression only,
whereas (by univariate analysis) the expression of all the
studied markers, as well as the tumor histological grade,
significantly correlated with the patient’s overall survival
(OS). Bymultivariate analysis using the Cox proportional
hazards model, among all variables considered, cav-1 was
the only independent prognostic marker related to OS
(relative risk5 13.92; P5 .013). Among grade II epen-
dymomas, only cav-1 correlated with poor OS (P5
.011), distinguishing 2 distinct subgroups of tumors
with different outcomes despite sharing identical
grading. All the patients studied carried wild-type cav-1
sequences, demonstrating that cav-1 overexpression is
not driven by activatingmutations, as previously reported
in other tumor types. Interestingly, after stratifying all
cases into 4 distinct groups according to cav-1 and
EGFR expression (cav-11/EGFR1, cav-12/EGFR2,
cav-11/EGFR2, and cav-12/EGFR1), the coexpres-
sion of cav-1 and EGFR identified a subset of patients
with definitively poor prognoses. Further studies are
needed to support this evidence on a larger scale and to
clarify how cav-1 and EGFR interaction can influence
tumor aggressiveness.
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A
dult ependymal tumors can have either an intra-
cranial or a spinal localization, and a different
gene expression profile between intra- and extra-
cranial neoplasms has been reported recently, defini-
tively identifying 2 distinct neoplastic entities.1
Adult intracranial ependymomas account for 2% of all
adult intracranial tumors,2 and this site is usually associ-
ated with a more aggressive clinical behavior.3 Except
for the location, a definite relationship among morpho-
logical features, phenotypic and/or molecular markers,
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and patient outcomes remains controversial. The influ-
ence of the tumor grade seems to be relevant in predict-
ing prognoses,2,4–9 despite conflicting results reported in
the literature as a consequence of interobserver variabil-
ity and World Health Organization (WHO) grading
system criteria that are equivocal when distinguishing
between classic (grade II) and anaplastic ependymomas
(grade III).10,11 However, within grade II ependymomas,
distinct groups of lesions with different prognoses can be
envisaged. Several putative prognostic indicators, such
as Ki-67 and p53, have been tentatively considered to
aid in distinguishing prognostic categories for ependy-
momas, but a reliable marker is still lacking.6,9,12–20
Recently, Kuncova et al.10 performed a systematic
review and meta-analysis of the published data on
immunohistochemical prognostic markers in intracra-
nial ependymomas, and they highlighted the role of
MIB-1 as the main prognostic marker that is significantly
related to poorer survival (with a cut-off value varying
from 1% to 25% in different studies). Similarly, epider-
mal growth factor receptor (EGFR) immunohistochem-
ical overexpression has been reported to be an
independent prognostic marker in intracranial ependy-
momas: it is useful to stratify patients within Grade II
lesions21 and is correlated with a reduced progression-
free survival.12 As reported for gliomas,22 a genetic
characterization of ependymomas may be informative
in order to define distinct prognostic categories. This
has been recognized among astrocyte-derived tumors
based on the switch-on of specific genes involved in
mesenchymal, proliferative, or proneural differen-
tiation,22–24 and specifically, a mesenchymal phenotype
has been identified as a predictor of a poorer progno-
sis.22 An alternative approach can be achieved at the
protein level by tracing the immune-phenotypic profile
using antibodies directed toward antigens expected to
be overexpressed because of the known gene activation.
Using such an approach, we discovered that a major
component of cell membrane scaffolds, caveolin-1
(cav-1), which is highly (but not exclusively) expressed
in mesenchymal/endothelial cells, bears diagnostic and
prognostic significance in astrocytic tumors and oligo-
dendrogliomas.25,26 The role of cav-1 in neoplastic
cells of various origins is to date debated and controver-
sial because it can act as a tumor promoter or inhibi-
tor.27–29 Recently, a cav-1 gene mutation (P132L) has
been reported to increase tumor aggressiveness and to
promote cell migration and invasiveness through an
interaction with new signaling protein partners that nor-
mally do not interact with cav-1 wild type (WT).30
In glioblastoma cells, in vitro experiments demon-
strated that cav-1 is upregulated and colocalizes with
EGFR.31 Such a pattern of expression may be significant
to the functional status of the receptor and therefore
could bear biological and therapeutic relevance, deserv-
ing further investigation in different glial tumors, such as
ependymomas.
On the basis of this evidence, we investigated, in a
series of adult intracranial ependymomas, (i) whether
cav-1 expression varies according to tumor grade and
Ki67, p53, and EGFR expression, (ii) whether cav-1
alone and/or in association with other markers may be
useful in predicting patient survival and in distinguishing
different outcome subgroups among tumors of an equiv-
alent grade (II), and (iii) whether cav-1 overexpression is
driven by an activating mutation.
Materials and Methods
Patients
A series of 22 adult intracranial ependymomas (operated
on between December 2001 and December 2006 in the
Neurosurgery Unit of the San Giovanni Battista-
Molinette Hospital of Turin, Policlinico Le Scotte of
Siena, Policlinico G. Rodolico of Catania, and
Neurosurgery Unit of the Cannizzaro Hospital of
Catania) were collected. The patients’ ages ranged
from 18 to 63 years (mean age, 38.7 years); 6 were
male and 16 were female. Biopsies and relapsed
tumors were excluded from the study. All cases were
reviewed by 2 independent pathologists, and the histo-
logical diagnoses were reconfirmed. The tumors were
classified according to the WHO Classification of
Brain Tumors (2007 edition). Fourteen of 22 (63.7%)
cases were Grade II ependymomas, and 8 of 22
(36.3%) were diagnosed as Grade III ependymomas
(anaplastic ependymomas).
Surgical treatment of patients consisted of gross total
or incomplete resection followed by postoperative
irradiation depending on the high grade or incomplete
resection of the tumor through a standardized thera-
peutic approach.
Table 1 details the clinical and the anatomical fea-
tures of the cases examined.
Table 1. Clinical and histological features of 22 patients
Characteristic Number of patients
Age (y)
Range 18–63
Mean 38.7
Sex
Men 6
Women 16
Tumor location
Ventricle (lateral or IIIth) 13
Parenchymal 9
Extent of surgery
Gross total removal 10
Incomplete resection 12
WHO histology
Grade II 14
Grade III 8
Follow-up (mo)
Range 13–109
Median 58.5
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Follow-up
The follow-up data were retrieved from the neuro-
oncologists’ clinical records. Overall survival (OS) was
determined as the time from the date of initial diagnosis
to the date of patient death.
The follow-up data were obtained for all patients. At
the end point of follow-up, 13 of 22 (59%) patients were
alive, whereas the remaining 9 of 22 patients (41%) had
died within a period of 1–12 months after surgery.
Among the living patients, follow-up ranged from 13
to 109 months with a mean of 58.5 months.
The study was performed according to the
standards of the Institutional Ethical Committee and
the Helsinki Declaration of 1975 as revised in 1983.
The Institutional Review Board of our hospital approved
the study. All tissue samples were anonymized by staff
who were not involved in the study, according to the
published procedures.32
Immunohistochemical Analysis
For each case, the surgical specimens were fixed in
4% buffered formaldehyde, routinely processed, and
paraffin embedded. Three-micrometer-thick sections
were prepared and routinely stained with hematoxylin
and eosin (H&E); additional sections, collected on
superfrost plus slides, were used for immunohistochem-
ical analysis. Immunohistochemical reactions using anti-
bodies anti-Ki-67 (monoclonal antibody, clone Mib1,
diluted 1:100; Dako), anti-p53 (monoclonal antibody,
clone D0-7, prediluted; Ventana-Diapath), anti-EGFR
(monoclonal antibody, clone 31G7, diluted 1:50;
Zymed), and anti-cav-1 (rabbit polyclonal antibody,
diluted 1:350; Santa Cruz) were performed in an
automated immunostainer (Ventana BenchMark
Auto-Stainer, Ventana Medical Systems). A double
cav-1/EGFR immunoreaction was also performed in
the 8 cases that were positive for both markers to recog-
nize their possible colocalization. Briefly, sections were
stained for EGFR in the Ventana automated immuno-
stainer, washed in phosphate buffered saline (PBS) sol-
ution, and treated with citrate solution for 10 min at
988C. The slides were then incubated with polyclonal
anti-cav-1 antibody (diluted 1:300, Santa Cruz) and sub-
sequently with a biotinylated secondary antibody and
alkaline phosphatase-conjugated streptavidin (Dako),
both for 30 min at room temperature. Slides were
washed in PBS solution and counterstained in alkaline
phosphatase blue substrate. Ki-67 and p53 immunohis-
tochemical variables were scored by evaluating the per-
centage of stained nuclei, counting positive nuclei of
10 separate fields at a ×400 magnification in the
tumor areas with the highest density of positive nuclei.
EGFR and cav-1 immunoreactivity was determined as
a percentage of positive cells (0%–100%), applying a
semiquantitative score determined on the evaluation of
the whole histological section. Appropriate positive
and negative controls for all of the studied antibodies
were used. Pathologists carrying out these analyses
were blinded to the clinical outcomes of patients.
Mutational Analysis
Formalin-fixed paraffin-embedded tumor sections were
collected for all the cases enrolled in this study. Genomic
DNA was extracted as described previously, and DNA
quantification was checked using a spectrophotometer.
The occurrence of cav-1 point mutations was assessed.
The analysis included the full cav-1 coding sequence.
Design and synthesis of exon-specific and sequencing
primers and the PCRs were performed as described33,
and amplicons were directly sequenced in an automatic
genetic analyzer (CEQ 8800, Genetic Analyzer,
Beckman-Coulter). The results of mutated samples were
validated at least twice, starting from independent PCRs.
Statistical Analysis
All data were analyzed with Statistical Package for the
Social Sciences version 17 (SPSS Inc.). Statistically sig-
nificant P-values were defined as ,.05.
Correlations between the immunohistochemical
results for the various markers (with continuous read-
outs) and the ependymoma histological grades were
evaluated using a Wilcoxon rank-sum test, whereas the
associations between the different immunohistochem-
ical markers were assessed by a Kendall correlation.
Univariate survival analysis was analyzed using a
Mantel–Cox test34 and depicted using the Kaplan–
Meier method.35 Multivariate survival analysis was per-
formed by the Cox proportional hazards model with a
backward stepwise selection procedure. To perform
the survival analysis, since the standard cut-off values
for p53, cav-1, and EGFR have not been set in the litera-
ture, we decided to use the median value as a cut-point
for each variable, as follows: p53 ¼ 8%, cav-1 ¼ 30%,
and EGFR ¼ 20%. The Ki-67 value was set according
to the literature (Ki-67 ¼ 1%).36
Results
Immunohistochemical Results: Correlations Between
Markers and Tumor Grade and Among Markers
Statistical analysis demonstrated a correlation between
ependymoma histological grades and Ki-67 (P ¼ .035),
cav-1 (P ¼ .001), and EGFR (P ¼ .001). No correlation
was observed between tumor grade and p53 immunor-
eactivity (P ¼ .18).
The cav-1 staining was localized both at the cell mem-
brane and within the cell cytoplasm; however, in Grade
III tumors, the membrane staining was prevalent and
more intense. The patterns of cav-1 immunoreactivity
are shown in Fig. 1.
A correlation between the studied markers indicated
that cav-1 expression significantly correlated with
Ki-67 (P ¼ .004), EGFR (P, .001), and p53 (P ¼
.001) immunoreactivity. In all of the 8 cases that were
both EGFR and cav-1 positive, a double cav-1/EGFR
immunoreaction was performed as well, which showed
that cav-1 and EGFR immunoreactivity colocalized in
Senetta et al.: Prognostic impact of cav-1 and EGFR in ependymomas
178 NEURO-ONCOLOGY † F E B R U A R Y 2 0 1 1
approximately 60% of the tumor cells (Fig. 1G–I). In
addition, Ki-67 expression significantly correlated with
p53 positivity (P ¼ .009). Aside from these, no other sig-
nificant correlations between the remaining immunohis-
tochemical markers studied were found.
Impact of Marker Expression on Survival
By univariate analysis, histological grade (P ¼ .018),
extent of surgery (P ¼ .02), Ki-67 (P ¼ .014), p53 (P ¼
.014), cav-1 (P ¼ .001), and EGFR (P ¼ .014)
expression significantly correlated with patient OS
(Table 2; Figs 2 and 3).
In Grade II ependymomas, only cav-1 correlated with
poor OS (P ¼ .011), indicating the presence of 2 distinct
subgroups of tumors with identical grading and different
outcomes (Fig. 3).
By the Cox proportional hazards model, among all of
the variables considered, cav-1 was the only independent
prognostic factor (relative risk ¼ 13.92; P ¼ .013).
Table 2. Grade, Ki-67, p53, cav-1, and EGFR expression in
censored patients by univariate analysis
N % Censored P-value
Grade
II 14 78.6 .018
III 8 25
Ki-67
Ki-67 ≤ 1% 7 100 .014
Ki-67. 1% 15 40
p53
p53 ≤ 8% 12 83.3 .014
p53. 8% 10 30
cav-1
cav-1 ≤ 30% 11 90.9 .001
cav-1 . 30% 11 20
EGFR
EGFR ≤ 20% 12 83.3 .014
EGFR. 20% 10 30
Fig. 1. Cav-1 and EGFR expression in ependymomas according to tumor grade. One case of Grade II ependymomas (A, H&E, 2×0) that proved
to be negative for cav-1 staining (B,×20). As for the majority of Grade II ependymomas studied, immunohistochemistry for EGFR was negative
as well (C, ×20). One case of a Grade III ependymoma (D, H&E, ×20) from our series displaying an intense cav-1 membrane staining (E, ×20)
and a diffuse EGFR positivity (F, ×40). In this case of a Grade III ependymoma (G, H&E, ×10), in the majority of positive cells, cav-1 (blue
staining) and EGFR (brown staining) were colocalized on the cell membrane, resulting in a black staining (H, ×20; I, ×40). The red
arrowhead indicates the internal positive control for cav-1 (blood vessel, in blue); the black arrowhead indicates a group of EGFR-positive/
cav-1 negative cells (brown staining). An area of cav-1 and EGFR coexpression is shown in the white frame (bar ¼ 100 mm).
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Finally, we decided to investigate whether cav-1
expression could impact the prognostic value of the
major known prognostic indicator in ependymomas,
EGFR. Therefore, we analyzed survival, stratifying all
cases into 4 distinct groups according to cav-1 and
EGFR expression (cav-1+/EGFR+, cav-12/EGFR2,
cav-1+/EGFR2, and cav-12/EGFR+) independently
of grade to define whether the coexpression of these 2
markers correlated with a significantly worse prognosis.
Strikingly, all patients with cav-1 and EGFR-positive
ependymomas (8 cases: 2 cases of Grade II and 6 of
Grade III) died within 12 months of diagnosis (P,
.005; Fig. 3).
Cav-1 Mutational Profiling in Supratentorial
Ependymomas
The mutational profile of cav-1 was assessed in all of the
studied cases of adult intracranial Grade II and Grade III
ependymomas. All the samples analyzed carried WT
cav-1 sequences.
Within the limits of the cohort in study, these results
suggest that cav-1 overexpression in aggressive ependy-
momas is not driven by activating mutations.
Discussion
In the present paper, we provide evidence that the coex-
pression of EGFR and cav-1 in adult intracranial epen-
dymomas significantly predicts a rapid unfavorable
outcome and that this immune-phenotypic pattern
identifies, among Grade II tumors, those with a poor
prognosis.
Cav-1 is one of the main components of cell mem-
brane unfolding called caveolae, which participate in
various cell functions under both physiological and neo-
plastic conditions. To date, the role of cav-1 in tumors is
still controversial: either promoting or inhibiting effects
in tumor growth have been reported, consistently with
cav-1 binding to heterogeneous “partners” involved in
cell-signaling cascades.27–29
Among the molecular mechanisms previously investi-
gated to explain the tumor-promoting role of cav-1, the
presence of a cav-1 activating mutation (P132L) proved
to be crucial in favoring invasiveness and aggressiveness
of the mammary cell line Met-1; the cav-1 (P132L)
mutation is supposed to favor the interaction of the
resulting protein product with new signaling
pro-oncogenic protein partners that do not normally
interact with cav-1 WT.30 In contrast, cav-1 gene ampli-
fication does not seem to be a suitable molecular mech-
anism because no amplification of the 7q31 region,
which harbors the cav-1 gene, was observed in a series
of recurrent prostate carcinomas.37
For this reason, in order to investigate the possible
molecular pathways involved in the observed overex-
pression of cav-1 associated with unfavorable outcomes
in our series, we checked the full coding sequence of
cav-1 and found no mutations.
Recently, our group and others reported that cav-1
expression in glial tumors varies according to histological
grades and predicts a poor prognosis in brain tumors with
oligodendroglial components.25,26 Also, a correlation
between cav-1 and p53, but not EGFR, has been reported
Fig. 2. The Kaplan–Meier plots of estimated OS time distribution
in relation to tumor grade (A), Ki-67 (B), and p53 (C) expression
(+, censored).
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in glial tumors.38 However, Abulrob et al.31 showed that
cav-1 and EGFR colocalize in glioblastoma cells, thus
influencing the EGFR-phosphorylated status in vitro.
The role and the biological significance of cav-1 inter-
action with EGFR have been recently discussed in
various studies, mainly addressed to breast cancer.39
Among others, Agelaki et al. reported that breast carci-
noma MCF7 cells expressing cav-1 exhibited higher
EGFR phosphorylation and Akt activation levels. In
addition, gefitinib treatment resulted in a more efficient
inhibition of downstream Akt and mitogen-activated
protein kinase in cav-1–positive neoplastic cells than in
those that were cav-1 negative.39 These data suggest a
crucial role for cav-1 in activating the EGFR cascade;
alternatively, they also confirm previous studies that
already demonstrated that following exposure to oxi-
dative stress, EGFR undergoes src-1– and cav-1–depen-
dent nuclear trafficking.40 Moreover, EGFR nuclear
translocation, which can be radiation induced and
occurs via caveolae, has been recently reported as
crucial in the acquisition of radioresistance.41
On the basis of this evidence, we decided to investi-
gate whether cav-1 could be expressed in ependymal
tumors as we previously reported in astrocytic-derived
gliomas and, if so, whether cav-1 and EGFR (which is
to date among the few prognostic markers for ependy-
mal tumors) can be coexpressed and this association
bears a prognostic significance. The results obtained in
this study demonstrate a correlation between cav-1 posi-
tivity and tumor grade and EGFR expression. In
addition, both cav-1 and EGFR have prognostic rel-
evance in distinguishing poor-prognosis patients, and
their coexpression strengthens their possible impacts
on the outcome. Mendrzyk et al.21 described previously,
via univariate analysis, that EGFR overexpression corre-
lates with a poor prognosis in intracranial ependymo-
mas, and they suggested that other effectors could
accompany EGFR expression. In our opinion, cav-1
could be among these partner molecules; in fact, recent
data proved cav-1 to be a marker of sensitivity to the
tyrosine kinase inhibitor dasatinib in solid tumor cell
lines, which display a phenotype characterized by a
mesenchymal transition.42 This result strengthens the
evidence for a functional involvement of cav-1 in the
src-family kinase pathway, which is required for
EGFR-initiated mitogenesis and could thus bear
Fig. 3. The Kaplan–Meier plots of estimated OS time distribution in relation to cav-1 and EGFR expression and cav-1/EGFR coexpression.
Plots refer to all 22 of the cases studied (A, C, and D) or to the subgroup of Grade II ependymomas only (B) (+, censored).
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biological and clinical relevance in EGFR-positive
tumors of glial/ependymal origin.42,43
Additionally, concerns about heterogeneous out-
comes among Grade II ependymomas had already
necessitated a molecular approach aimed at identifying
specific chromosomal abnormalities associated with
different prognoses. This approach could account for a
novel, more objective alternative/additional classifi-
cation in addition to histological grades.21,44 We
suggest that an immunohistochemical approach (such
as has already proven useful with EGFR) to distinguish
prognosis subgroups among grade II intracranial epen-
dymomas21 using a marker such as cav-1, which is
easily detectable and has a good internal positive
control constituted by endothelial cells, alone or in com-
bination with EGFR, might help in recognizing more
aggressive lesions in a pool of relatively benign tumors
and thus be useful as a first-step prognostic screening.
In our series, multivariate analysis indicated that cav-1
is the only molecular marker significantly associated
with patient outcomes. Owing to the cav-1 involvement
in different signaling cascades,42 its expression could
represent a preliminary signature for potential future
adjuvant issue targeting.45
It should be stressed that although in the present
study we focused on the interaction between cav-1 and
EGFR, due to the previously reported unfavorable role
of the latter in ependymomas,21 a large cohort of
alternative molecules could interact with cav-1 within
plasma membrane specializations, such as those
described as “signalosomes” and involving tyrosine
kinase receptors other than EGFR. Therefore, the find-
ings described here could be extended to other proteins
potentially associated with the cav-1–mediated modu-
lation of pro-oncogenic signaling events.
Although the number of cases of this series is limited,
the sample can be considered representative as a homo-
geneous group of supratentorial and adult ependymal
tumors; therefore, due to the actual lack of reliable prog-
nostic indicators in intracranial ependymomas, the
potential impact of the results presented here is worth
consideration as pivotal preliminary evidence to be con-
firmed in a larger series and to be investigated under a
functional approach.
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